Brno Oncology Days Nursing Conference



Conference Programme

23–25 October 2024 Brno, Exhibition Centre, Hall E





www.onkologickedny.cz/en







NETWORKING BRINGS PROFFESIONALS TOGETHER

Join us in Brno and network with your colleagues, interact with key opinion leaders, ask questions and debate on burning topics in the field of medical oncology in a uniquely meaningful way.

SEE YOU AT BOD 2025 22-24 OCTOBER 2025

CONTENT

Introduction	4
Conference plan	6

THURSDAY / R. WERNER HALL	10
International Brno Oncology Days	10
Keynote Lecture: Cancer lethality – an indicator of reality	10
Clinical Research	10
Genitourinary Tumours	10
Breaking News in Oncology 2024	11
Meet the Experts	11

FRIDAY / R. WERNER HALL	12
International Brno Oncology Days	12
Head and Neck Tumours	12
Sarcomas	12
Precision Medicine	12

INVITED SPEAKERS	14
Dirk Arnold	14
Andreas Dietz	15
Rafał Dziadziuszko	16
Gro Live Fagereng	17
Jakub Kucharz	18
Florian Lordick	19
József Lövey	20
Álvaro Pinto	21
Silke Tribius	22
Martin J. van den Bent	23
Winette van der Graaf	24
Maximilian Schmid	25



INTRODUCTION

Dear colleagues and friends,

On behalf of the Masaryk Memorial Cancer Institute and the Organizing Committee, we are pleased to **welcome you to the 48th Brno Oncology Days (BOD) and the 38th Nursing Conference.** The Brno Oncology Days represent **the largest national professional event with an international dimension**, encompassing all professions involved in oncology.

Last year, we welcomed 2,200 participants, including 23 invited international speakers, in the traditional setting of the Congress Center in Hall E at the Brno Exhibition Centre. During the three-day conference, 342 contributions were presented, with a total of 307 oral presentations delivered across 40 educational blocks and 10 free communication blocks.

This year, the Brno Oncology Days will again start with the **Glio Meeting**, a multidisciplinary gathering of experts on brain tumours, followed by seminars on new developments in **gynecologic** and **geriatric oncology**. Additionally, we should not forget the educational seminar for **general practitioners and non**-**-oncologists**, which will focus on both cancer prevention and follow-up care after cancer treatment. An integral part of the BOD is also the topic of translational research as well as the clinically oriented section of case reports.

In addition to the traditional educational seminars focused on breast cancer, lung tumours, tumours of the gastrointestinal and urogenital tracts, immunotherapy, targeted therapy, surgical oncology, and palliative care, the professional program also includes special blocks dedicated to preventive medicine, legal issues in healthcare, and the increasing role of artificial intelligence in diagnosis and treatment. Due to the great success of last year, we are again including the **Psycho-oncology Conference** in this year's schedule, this time subtitled Resilience: Coping with Adversity.

For the fourth consecutive year, we are also preparing the International Brno Oncology Days (I-BOD), which will take place on October 24-25. The idea behind the International Brno Oncology Days is to deepen cooperation among specialists in the Central European region. This year, our invitation was accepted by a number of leading experts as well as young physicians and scientists from neighboring countries, including university centers in Vienna, Oslo, Amsterdam, Bratislava, Hamburg, Leipzig, and Budapest. The diverse program offers a wide range of symposia, from educational sessions informing about news from international conferences such as ASCO and ESMO to the case-based meeting Meet the Experts. In an otherwise clinically oriented program, we have not overlooked the crucial importance of clinical research for practice; therefore, the entire I-BOD program will begin with a discussion on projects from both senior experts and junior clinical researchers. We believe we can establish a creative and pleasant academic environment that fosters collaboration not only among experts in their fields but also encourages mutual cooperation among the emerging generation of young physicians and clinical research professionals.

From the **Nursing Conference** varied program, we would like to highlight the presentation of the European Society of Oncology Nurses and its visions, the issues of medical simulation, and innovations in diagnostic radiography, nuclear medicine, and radiotherapy. Also included are popular workshops aimed at improving practical skills. We are delighted that many professional societies have accepted the patronage of the Brno Oncology Days, with **ESMO** and **The Czech Society for Oncology** (ČOS) serving as our guarantors once again.

We are always pleased that participants can enjoy our conferences as both highly professional and enjoyable social events, serving as a place where they can meet their colleagues and friends. Our firm belief is that this will be the case again this year. Alongside Wednesday's opening ceremony, we will also welcome distinguished guests from the I-BOD. On Thursday, a **gala evening** will take place at the International Hotel, including an awards ceremony.

Last but not least, we would like to express our profound gratitude to all sponsors and exhibitors for their financial support, without which an event of this magnitude would not have been possible.

In closing, we wish the conference success and look forward to your participation.




Assoc Prof. Radka Lordick Obermannová, MD, PhD Chair of the BOD Program Committee



PhDr. Jana Kocourková, MBA Chair of the Nursing Conference Program Committee




Prof. Marek Svoboda, MD, PhD General Director of the Masaryk Memorial Cancer Institute



BRNO EXHIBITION CENTRE

Brno Oncology Days 2024



CONFERENCE PROGRAMME

Thursday 24	International Brno Oncology Days
October 2024	R. Werner Hall
8:00-8:30	Keynote Lecture: Cancer lethality – an indicator of reality
8:30-8:50	COFFEE BREAK
8:50-10:20	Clinical Research
10:20–10:30	BREAK
10:30–12:00	Genitourinary Tumours
12:00-13:00	LUNCH
13:00–14:00	Satellite Symposium AstraZeneca
14:00-14:10	BREAK
14:10–15:40	Breaking News in Oncology 2024
15:40–16:00	COFFEE BREAK
16:00–17:30	Meet the Experts (Young Oncologists Programme)
18:00–24:00	GALA DINNER

Friday 25	International Brno Oncology Days
October 2024	R. Werner Hall
7:30-8:30	Satellite Symposium MSD
8:30-8:40	BREAK
8:40–10:10	Head and Neck Tumours
10:10-10:30	COFFEE BREAK
10:30-12:00	Sarcomas*
12:00-12:10	BREAK
12:10–13:40	Precision Medicine
13:40–14:30	LUNCH

*Simultaneous interpretation is provided in this session.

R. Werner Hall

Thursday 24 October

08:00-08:30 08:00 69. 08:30	KEYNOTE LECTURE: CANCER LETHALITY – AN INDICATOR OF REALITY Chair: J. Žaloudík (Brno) CANCER LETHALITY – AN INDICATOR OF REALITY J. Žaloudík (Brno) Coffee break	10:00 10:10 10:20	76.	FLUORESCENCE-GUIDED SURGERY: AN OVERVIEW OF THE CURRENT STATUS AND OUR STUDY S. Jaroščiaková, T. Haruštiak, R. Lischke (Prague) Discussion Break
08:50-10:20 08:50 70.	IBOD CLINICAL RESEARCH Chairs: T. Kazda, L. Hernychová, J. Žaloudík (Brno) HYPOFRACTIONATED RT AND IMMUNOTHERAPY	10:30-	12:00	IBOD GENITOURINARY TUMOURS Chairs: A. Poprach, M. Staník, M. Matějů, A. Pinto, J. Kucharz (Brno, Prague, Madrid, Warsaw)
	IN ECURRENT/PERSISTENT H&N CANCER PATIENTS D. Blakaj (Columbus)	10:30	77.	HOW TO IMPROVE THE OUTCOMES OF RADICAL CYSTECTOMY? M. Staník (Brno)
09:05 71.	HISTONE LYSINE DEMETHYLASES (KDM) AND CANCER CELL CHEMORESISTANCE T. Eckschlager, M. Rychlá, N. Podhorská, J. Hraběta,	10:45	78.	NEOADJUVANT TREATMENT IN MUSCLE-INVASIVE BLADDER CANCER M. Matějů (Prague)
09:20 72.	A. Vícha (Prague) EX VIVO TRANSDUCTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPC) WITH	11:00	79.	ADJUVANT TREATMENT OF MUSCLE-INVASIVE UROTHELIAL CARCINOMAS A. Poprach, R. Lakomý, M. Staník (Brno)
	TROPISM-OPTIMIZED ADENO-ASSOCIATED VIRUS (AAV) VARIANTS A. Überla (Leipzig)	11:15	80.	CURRENT OPTIONS FOR FIRST-LINE PALLIATIVE SYSTEMIC THERAPY IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA
09:30 73.	OVERALL AND PROGRESSION-FREE SURVIVAL OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): THE HUNGARIAN (HUN)	11:30	81.	A. Pinto (Madrid) MODERN TREATMENT OF METASTATIC UROTHELIAL CARCINOMA AFTER FAILURE
09:40 74.	EXPERIENCE OF THE PROMETCO STUDY R. Szöllősi (Budapest) OVERCOMING HER2 RESISTANCE: SYNERGY OF	11:45		OF FIRST-LINE PALLIATIVE TREATMENT J. Kucharz (Warsaw) Discussion
09:50 75.	HDAC AND EGFR INHIBITORS IN GASTRIC CANCER T. Zenz (Leipzig) SENTINEL NODE IN COLON CANCER – A PATH	12:00		Lunch
	TO PERSONALIZED TREATMENT BETWEEN RESEARCH AND CLINICAL APPLICATION			

T. Staněk (Brno)

14:10-15:40		IBOD BREAKING NEWS IN ONCOLOGY 2024	16
		Chairs: D. Arnold, M. van den Bent, D. Cibula,	
		R. Dziadziuszko, M. Holánek (Hamburg, Rotterdam,	
		Prague, Gdańsk, Brno)	
14:10	85.	BREAST CANCER	
		M. Holánek (Brno)	
14:25	86.	GYNECOLOGICAL TUMOURS	16
		D. Cibula (Prague)	
14:40	87.	2024: UPDATE ON COLORECTAL CANCER	
		TREATMENT GUIDELINES	
		D. Arnold (Hamburg)	
14:55	88.	THE NEW HIGHWAYS ON LUNG CANCER	
		ROADMAP FOR 2030	16
		R. Dziadziuszko (Gdańsk)	
15:10	89.	LOW-GRADE GLIOMAS	
		M. van den Bent (Rotterdam)	16
15:25		Discussion	
15:40		Coffee break	

16:00-17:30	IBOD MEET THE EXPERTS (Young Oncologists
	Programme)
	Moderator: T. Sokop (Brno)
	Chairs: R. Dziadziuszko, O. Bílek, K. Kopečková,
	F. Lordick, D. Arnold, J. Kucharz, A. Poprach
	(Gdańsk, Brno, Prague, Lepzig, Hamburg, Warsaw)
16:00 90.	LUNG ADENOCARCINOMA WITH ROS-1
	REARRANGEMENT OCCURRING DURING
	SYSTEMIC TREATMENT FOR EGRF NON-MUTATED
	DISEASE
	M. Čunderlík, J. Dolinský, L. Šebesta, M. Chovanec,
	R. Godál (Bratislava)
16:20 91.	GASTROINTESTINAL STROMA TUMOURS -
	TARGETED TREATMENT BEYOND IMATINIB
	M. Bischof (Lepzig)
16:40 92.	NONOPERATIVE MANAGEMENT OF DMMR
	RECTAL CANCER PATIENT TREATED WITH
	IMMUNOTHERAPY
	M. Kysela (Brno)
17:00 93.	IMMUNOMODULATORY EFFECT OF
	CABOZANTINIB ON CD4 LYMPHOCYTES
	P. Domański (Warsaw)
17:20	Discussion



R. Werner Hall

Friday 25 October

08:40-10:10	IBOD HEAD AND NECK TUMOURS
	Chairs: V. Rak, S. Tribius, M. Vošmik
	(Brno, Hamburg, Hradec Králové)
08:40 202	2. RADIATION THERAPY IN HPV-POSITIVE HEAD AND
	NECK CANCERS
	M. Vošmik (Hradec Králové)
08:55 203	5. STATE OF ART OF CURRENT HEAD AND NECK
	TREATMENT
	S. Tribius (Hamburg)
09:15 204	ROLE OF MODERN PRECISION SURGERY IN
	CURRENT HEAD AND NECK THERAPY CONCEPTS
	A. Dietz (Leipzig)
09:35 205	5. COMPREHENSIVE RECONSTRUCTION OF SEVERE
	OROFACIAL DEFECTS – CHALLENGES AND
	PITFALLS
	Z. Daněk (Brno)
09:50 206	5. PERSISTENCE OF NUTRITION AND SURVIVAL
	IN HEAD AND NECK CANCER PATIENTS, BASED
	ON REAL-LIFE DATA
	J. Lövey, B. Belák, C. Blasszauer, D. Reibl, A. Molnár
	(Oslo, Budapest)
10:05	Discussion
10:10	Coffee break
10:30-12:00	D IBOD SARCOMAS*
10.00 12.00	Chairs: D. Adámková, W. van der Graaf, M. Schmid,
	K. Kopečková (Brno, Amsterdam, Vienna, Prague)
10:30 207	
	THEORY TO DAILY PRACTICE
	D. Adámková, J. Mužík, L. Dušek (Brno, Prague)
10:40 208	
	M. Schmid (Vienna)

*Simultaneous interpretation is provided in this session.

11:00	209.	SYSTEMIC TREATMENT OF SARCOMAS
		W. van der Graaf (Amsterdam)
11:30	210.	CHALLENGES IN THE SURGICAL TREATMENT
		OF RETROPERITONEAL SARCOMAS
		P. Hladík (Prague)
11:40	211.	INTERVENTIONAL RADIOLOGIST AND MSK
		TUMOURS – THE NEWS
		J. Křístek, S. Romža, M. Pacal, M. Straka, P. Opletal
		(Brno)
11:50		Discussion
12:00		Break
12:10-	13:40	IBOD PRECISION MEDICINE
		Chairs: P. Grell, W. van der Graaf, S. Tribius,
		G. Fagereng, A. Pinto (Brno, Amsterdam, Hamburg,
		Oslo, Madrid)
12:10	212.	PRECISION ONCOLOGY IN SARCOMAS
		W. van der Graaf (Amsterdam)
12:25	213.	PRECISION ONCOLOGY IN HEAD AND NECK
		TUMOURS
		S. Tribius (Hamburg)
12:40	214.	PRIME-ROSE – A EUROPEAN PRECISION
		CANCER MEDICINE TRIAL NETWORK AND
		IMPLEMENTATION INITIATIVE
		G. Fagereng (Oslo)
12:55	215.	GENESIS – MOLECULAR ALTERATIONS IN SOLID
		TUMOURS – CZECH NATIONAL PROJECT
		P. Grell (Brno)
13:10	216.	IMPLEMENTATION OF PRECISION MEDICINE
		IN UROLOGIC ONCOLOGY
		A. Pinto (Madrid)
13:25		Discussion
13:40		Lunch





Prof. Dirk Arnold, MD, PhD Asklepios Tumorzentrum Hamburg, Germany

2024: UPDATE ON COLORECTAL CANCER TREATMENT GUIDELINES Thursday 24. 10. 2024, 2:40 p.m., R. Werner Hall

Dirk Arnold undertook specialist training at Charité, Humboldt University in Berlin. Subsequently, he trained as a medical oncologist and specialist in palliative care at the Martin Luther University Halle-Wittenberg in Halle, Germany. He has held the positions of Professor and Chair of the Gastrointestinal Cancer Unit at the Martin Luther University Halle-Wittenberg. In 2010, he was appointed as Professor for Oncology at University Hamburg, and held the position as Director of the University Cancer Center Hamburg. In 2015, he additionally got appointed as Director of oncology services at the Instituto CUF de Oncologia in Lisbon, Portugal. Since 2017, Professor Arnold is Director of Asklepios Tumorzentrum Hamburg, a large network cancer centre, and chairman of the Oncology Department at AK Altona, Hamburg.

His main research interests include the treatment of gastrointestinal and genitourinary cancers, specifically in molecular-targeted therapies, immunotherapy, multimodal treatment strategies and early drug developments. He is also interested in research network structures and methodology of clinical research and benefit evaluation procedures, as well as in palliative and supportive care.

Professor Arnold has served more than 10 years as Chair of the Colorectal Cancer Study Group of the Working Group for Internal Oncology. He is a key member of several German and other international cancer societies, including ESMO where he serves as a Council Member and Chairman of the Compliance Committee. He served as Section Editor for GI Cancers in the Guideline Committee and is Section Editor for GI Cancers with Annals of Oncology. He is also a Co-Chairman of the Task Force on Colorectal Cancer and the board of the Gastrointestinal Cancer Study Group of EORTC. Dr Arnold has co-authored more than 250 articles in peer-reviewed journals.

Selected recent papers:

 Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y.; RAGNAR Investigators. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol 2023; 24(8): 925–935.
 Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csöszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D et al.; FRESCO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 2023; 402(10395): 41–53.

 Taieb J, Basile D, Seligmann J, Argiles G, André T, Gallois C, Goldberg RM, Yothers G, Sobrero A, Meyerhardt JA, Souglakos J, Labianca R, Iveson T, Church DN, Arnold D, Tie J, Gill S, Laurent-Puig P, Y

oshino T, Lonardi S, Shi Q. Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts. Eur J Cancer 2024; 206: 114118.

On the occasion of Brno Oncology Days, Prof. Arnold will deliver an invited lecture on the topic "2024: Update on colorectal cancer treatment guidelines".



Prof. Andreas Dietz, MD, PhD

ENT University Clinic Leipzig, Germany

ROLE OF MODERN PRECISION SURGERY IN CURRENT HEAD AND NECK THERAPY CONCEPTS Friday 25. 10. 2024, 9:15 a.m., R. Werner Hall

Since April 2004, Prof. Dr. Andreas Dietz is Chair of the ENT University Clinic Leipzig. He is full-trained ENT and head and neck surgeon and has special qualification in plastic surgery and Oncology. His scientific work is reflected in numerous studies and translational projects on head and neck cancer. He is internationally known as an expert in this field. He was President of the German Society for ENT – Head and Neck Surgery (DGHNO-KHT) from 2019 to 2020 and is speaker of the interdisciplinary group of Head and Neck Cancer of the German Cancer Society (IAG-KHT).

He holds visible positions on numerous international committees like membership of the Board of Directors of the European Head and Neck Society. He is speaker of the board of the Innovation Center for Computer-Assisted Surgery (ICCAS) Leipzig. He is a member of the Board of Directors of the Global Online Fellowship Initiative at Sloan Kettering Memorial Cancer Center in New York and Chair of the Surgery Subcommittee of the EORTC Head and Neck Group. He is honorary member of the Royal Belgian, the Austrian and Czech ENT Society and the Indian Head and Neck Foundation.

Andreas Dietz is author/co-author of more than 600 pub-med listed publications. He coordinates the German S3-Guideline for oropharyngeal and hypopharyngeal cancer. Andreas Dietz was honored with the DGHNO-KHC Medal of Merit, the Order of Merit of the Free State of Saxony in 2022 and with the EHNS Award in 2023.

Selected recent papers:

1. Mattavelli D, Wichmann G, Smussi D, Paderno A, Plana MS, Mesia RN, Compagnoni M, Medda A, Chiocca S, Calza S, Zhan Y, Rognoni C, Tarricone R, Stucchi E, Lorini L, Gurizzan C, Khelik K, Hovig E, Dietz A, Piazza C, Bossi, P. Is precision medicine the solution to improve organ preservation in laryngeal/ hypopharyngeal cancer? A position paper by the Preserve Research Group. Front Oncol 2024; 14: 1433333.

 Singer S, Roick J, Gose A, Oeken J, Herzog M, Pabst F, Plontke SK, Boehm A, Dietz A, Büntzel J, Vogel HJ, Fabian A, Wollenberg B, Taylor K, Gouveris H, Busch CJ, Guntinas-Lichius O. Patients' Reflections on Treatment Decision After Surgery for Laryngeal Cancer. JAMA Otolaryngol Head Neck Surg 2024; 150(8): 666–676.

3. Katalinic M, Schenk M, Franke S, Katalinic A, Neumuth T, Dietz A, Stoehr M, Gaebel J. Generation of a Realistic Synthetic Laryngeal Cancer Cohort for Al Applications. Cancers (Basel) 2024; 16(3): 639.

4. Rast J, Zebralla V, Dietz, A, Wichmann G, Wiegand, S. Cancer--associated financial burden in German head and neck cancer patients. Front Oncol 2024; 14: 1329242.

5. Röhl L, Wellhausen J, Berszin M, Krücken I, Zebralla V, Pirlich M, Wiegand S, Dietz A, Wald T, Wichmann G. Immune checkpoint blockade induced shifts in cytokine expression patterns in peripheral blood of head and neck cancer patients are linked to outcome. Front Immunol 2023; 14: 1237623.

On the occasion of Brno Oncology Days, Prof. Dietz will deliver an invited lecture on the topic "Role of modern precision surgery in current head and neck therapy concepts".



Prof. Rafał Dziadziuszko, MD, PhD

Department of Oncology and Radiotherapy of the Medical University of Gdansk, Poland

THE NEW HIGHWAYS ON LUNG CANCER ROADMAP FOR 2030 Thursday 24. 10. 2024, 2:55 p.m., R. Werner Hall

Prof. Rafał Dziadziuszko completed his MD (1994) and PhD (2003) at the Medical University of Gdańsk. He received board certifications in Radiation Oncology (2001) and Medical Oncology (2004). He completed translational cancer research fellowship at the University of Colorado Cancer Center. Between 2005 and 2007 he worked on predictive assays for EGFR targeted therapies in lung cancer, including immunohistochemistry, gene copy number, and activating mutations. His fellowships were funded by the International Union Against Cancer and the International Association for the Study of Lung Cancer. He then returned to his home institution to serve as a deputy chair, and currently chair of the Department of Oncology and Radiotherapy. Between 2013 and 2018, he served as a national consultant for Radiation Oncology, overseeing the development of modern radiotherapy care in Poland and curriculum of Radiotherapy residency program.

Prof. Dziadziuszko's main interests include lung cancer translational and clinical research, and he is a co-author of over 200 peer-reviewed articles. He is a member of the European Society for Radiotherapy and Oncology, International Association for the Study of Lung Cancer, European Society of Medical Oncology, European Organisation for Research and Treatment of Cancer – Lung Cancer Group, American Society of Clinical Oncology and associate editor of Journal of Thoracic Oncology. He participated in the organisation of several academic and industry-sponsored clinical research studies with focus on lung cancer radiotherapy fractionation, combined modality treatment, and early drug development. In 2017, he received Heine H. Hansen Award for global contribution to lung cancer research and care.

His current work includes evaluation of novel molecular targeted therapies and immune checkpoint inhibitors for lung cancer, evaluation of novel radiotherapy strategies in thoracic malignancies and research on lung cancer screening programs.

Selected recent papers:

1. Houda I, Dickhoff C, Uyl-de Groot CA, Damhuis RAM, Reguart N, Provencio M, Levy A, Dziadziuszko R et al. Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective. Lancet Reg Health Eur 2024; 38: 100841.

 Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2024; 390(2): 118–131.

 Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, et al.; DeLLphi-301 Investigators. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. N Engl J Med 2023; 389(22): 2063–2075.

4. Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol 2022; 33(5): 466–487.

On the occasion of Brno Oncology Days, Prof. Dziadziuszko will deliver an invited lecture on the topic "The new highways on lung cancer roadmap for 2030".



Gro Live Fagereng, PhD

Institute for Cancer Research, Oslo University Hospital, Norway PRIME-ROSE – A EUROPEAN PRECISION CANCER MEDICINE TRIAL NETWORK AND IMPLEMENTATION INITIATIVE Friday 25. 10. 2024, 12:40 p.m., R. Werner Hall

Dr. Gro Live Fagereng obtained her PhD in Molecular Biology from the University of Oslo in 2013. She has accumulated extensive experience in the pharmaceutical industry as a senior research consultant before transitioning to a strategic advisor role at the Institute for Cancer Research at Oslo University Hospital. Dr. Fagereng also served as a Senior Advisor at the Norwegian Hospital Procurement Trust, where she played a pivotal role in price negotiation and procurement of new cancer drugs for all hospitals in Norway.

She coordinates the Precision Cancer Medicine initiatives at Oslo University Hospital, where her work encompasses research strategy and coordination of key projects. These include the national cancer medicine trial IMPRESS-Norway, the national infrastructure for precision diagnostics (InPreD), and the publicprivate collaboration CONNECT for implementing precision medicine. Currently, she works as a Project Manager for PRIME-ROSE, a Horizon Europe Mission on Cancer project with 24 partners from altogether 18 European countries.

Selected recent papers:

 Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, Helland Å; InPreD Consortium; IMPRESS-Norway Consortium. IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results. Acta Oncol 2024; 63: 379–384.
 Taskén K, F Haj Mohammad S, Fagereng GL, Sørum Falk R, Helland Å, Barjesteh van Waalwijk van Doorn-Khosrovani S, Steen Carlsson K, Ryll B, Jalkanen K, Edsjö A, Russnes HG, Lassen U, Hallersjö Hult E, Lugowska I, Blay JY, Verlingue L, Abel E, Lowery MA, Krebs MG, Staal Rohrberg K, Ojamaa K, Oliveira J, Verheul HMW, Voest EE, Gelderblom H; PRIME-ROSE Consortium and the PCM4EU Consortium. PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe. Acta Oncol 2024; 63: 385–391.

 Fagereng GL, Morvik AM, Reinvik Ulimoen S, Ringerud AM, Dahlen Syversen I, Sagdahl E. The impact of level of documentation on the accessibility and affordability of new drugs in Norway. Front Pharmacol 2024; 15: 1338541.

4. Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES; CONNECT Public--Private Partnership Consortium; Enerly E, Fagereng GL, Flobak Å, Gilie B. Giertsen BT. Guren TK. Heix J. Hovig E. Hovland R: InPreD-Norway and National Molecular Tumor Board Consortium; IMPRESS-Norway Consortium; Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å. A national precision cancer medicine implementation initiative for Norway. Nat Med 2022; 28(5): 885-887. 5. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Biørge L. Blix E. Bierkehagen B. Brabrand S. Cameron MG. Dalhaug A. Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D, Hjortland GO, Hovig E, Hovland R, Iversen AC, Janssen E, Kyte JA, von der Lippe Gythfeldt H, Lothe R, Lund JÅ, Meza-Zepeda L, Munthe-Kaas MC, Nguyen OTD, Niehusmann P, Nilsen H, Puco K, Ree AH, Riste TB, Semb K, Steinskog ESS, Stensvold A, Suhrke P. Tennøe Ø. Tiønnfiord GE. Vassbotn LJ. Aas E. Aasebø K. Tasken K. Smeland S. Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. J Transl Med 2022; 20(1): 225. Erratum in: J Transl Med 2022; 20(1): 317.

On the occasion of Brno Oncology Days, Dr. Fagereng will deliver an invited lecture on the topic "PRIME-ROSE – A European precision cancer medicine trial network and implementation initiative".



Jakub Kucharz, MD, PhD

Maria Sklodowska-Curie National Research Institute of Oncology, Poland MODERN TREATMENT OF METASTATIC UROTHELIAL CARCINOMA AFTER FAILURE OF FIRST-LINE PALLIATIVE TREATMENT Thursday 24. 10. 2024, 11:30 a.m., R. Werner Hall

Dr. Kucharz is associate professor of medical oncology at Maria Sklodowska-Curie National Research Institute of Oncology. He graduated Jagiellonian University Medical College. Dr. Kucharz is board-certified medical oncologist focused on genitourinary oncology and supportive care.

He is General Secretary of the Executive Board of Polish Society of Clinical Oncology and secretary of the Supportive Care Section of Polish Society of Clinical Oncology. He is also the member of European Society for Clinical Oncology.

Dr. Kucharz research interests are focused on prognostic and predictive factors for targeted therapies and immunotherapy, adverse events management and treatment of critically-ill germ cell tumor patients.

He published over 60 articles in peer-reviewed journals. He is also an coauthor of clinical practice guidelines (GU tumors) of Polish Society of Clinical Oncology. Dr. Kucharz serves as peer reviewer for several medical journals.

Selected recent papers:

 Santoni M, Buti S, Myint ZW, Maruzzo M, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L et al. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? Eur Urol Oncol 2024; 7(1): 102–111.

 Incorvaia L, Monteiro FSM, Massari F, Park SH, Roviello G, Fiala O, Myint ZW, Kucharz J, Molina-Cerrillo J, Santini D et al. Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations. Cancer Immunol Immunother 2024; 73(8): 142.
 Kuncman Ł, Orzechowska M, Milecki T, Kucharz J, Fijuth J. High FLT3

expression increases immune-cell infiltration in the tumor microenvironment and correlates with prolonged disease-free survival in patients with non-small cell lung cancer. Mol Oncol 2024; 18(5): 1316–1326. 4. Santoni M, Rizzo A, Kucharz J, Mollica V, Rosellini M, Marchetti A, Tassinari E, Monteiro FSM, Soares A, Molina-Cerrillo J, Grande E, Battelli N, Massari F. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 metaanalysis. Cancer Immunol Immunother 2023; 72(6): 1365–1379.
5. Fiala O, Buti S, Takeshita H, Okada Y, Massari F, Palacios GA, Dionese M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R.... Kucharz J et al. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. Cancer Immunol Immunother 2023; 72(11): 3665–3682.

On the occasion of Brno Oncology Days, Dr. Kucharz will deliver an invited lecture on the topic "Modern treatment of metastatic urothelial carcinoma after failure of first-line palliative treatment".



Prof. Florian Lordick, MD, PhD.

University Cancer Center Leipzig, Leipzig University Medical Center, Leipzig, Germany

RECENT ADVANCES FOR SYSTEMIC TREATMENT OF UPPER GI TUMOURS Thursday 24. 10. 2024, 9:20 a.m., J. Bakeš Hall

Florian Lordick is a Full Professor of Medicine at the University of Leipzig, Germany. He was appointed as director of the University Cancer Center Leipzig in 2012, which, in collaboration with the University of Jena Medical Center, recently was awarded as one of 15 German Oncology Centers of Excellence and receives funding from the German Cancer Aid. He also is head of the Department of Medicine (oncology, gastroenterology, hepatology, and pulmonology) at the University of Leipzig Medical Center.

Dr. Lordick's scientific focus is on clinical and translational research in immuno-oncology and targeted treatment of cancer, with a specific focus on gastrointestinal tract tumours. He has a great interest in multimodality treatment of Gl cancers, in personalized medicine and in survivorship topics. His research is funded by the German Cancer Aid, the German Ministry of Education and Research and by the European Commission.

Dr. Lordick has authored and co-authored more than 400 peer-reviewed and PubMed-listed articles. Dr. Lordick served as Director of Education at the European Society for Medical Oncology (ESMO) from 2019 to 2022, as president of the International Gastric Cancer Association (IGCA) and he is a former member of the executive board of the German Cancer Society and former chair of the EORTC Gastrointestinal Tract Cancer Working groups.

He holds reviewer and advisory roles at various research funding organizations and European comprehensive cancer centers. He also is the newly appointed Editor-in-Chief of ESMO Gastrointestinal Oncology, official scientific journal of the European Society for Medical Oncology.

Selected recent papers:

1. Kroese TE, Bronzwaer S, van Rossum PSN, Schoppman SF, Deseyne PRAJ, van Cutsem E, Haustermans K, Nafteux P, Thomas M, Obermannova R, Mortensen HR, Nordsmark M, Pfeiffer P, Elme A, Adenis a, Piessen G, Bruns CJ, Lordick F et al. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). Eur J Cancer 2024; 204: 114062.

2. Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 2023; 401(10389): 1655–1668.

3. Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 2023; 29(8): 2133–2141.

4. Lordick F, Thuss-Patience P, Bitzer M, Maurus D, Sahin U, Türeci Ö. Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer. J Cancer Res Clin Oncol 2023; 149(9): 5937–5950.

On the occasion of Brno Oncology Days, Prof. Lordick will deliver an invited lectures on the topic "Recent advances for systemic treatment of upper GI tumours".



József Lövey, MD, PhD Oslo University Hospital, Oslo, Norway

PERSISTENCE OF NUTRITION AND SURVIVAL IN HEAD AND NECK CANCER PATIENTS, BASED ON REAL-LIFE DATA Friday 25. 10. 2024, 9:50 a.m., R. Werner Hall

József Lövey has been graduated from the Semmelweis University of Medicine in 1993. He started to work at the National Institute of Oncology comprehensive cancer centre in Budapest the same year. He got his specialisation in radiotherapy in 1997 and in medical oncology in 2000. He earned a Ph.D. degree in 2005 in the topic of radiation sensitisation of cancer cells. Become habilitated to the University of Pécs in 2011. Between 1993 and 2024 he had several positions at the National Institute of Oncology: became consultant in 2005, deputy head of radiation oncology department in 2009, director of international relations between 2009–2013, medical director between 2013 and 2024, and director of quality between 2022 and 2024. Between 2013 and 2024 he was associate professor at the Semmelweis University of Medicine in Budapest.

Among other roles, he was the president of the Hungarian Society for Radiation Oncology between 2012 and 2014 and he is currently the president of the Hungarian Society of Oncologists. He was the member of the executive board of the Organization of European Cancer Institutes (OECI) between 2015 and 2024, member of the Board of Accreditation of OECI and the Chair of the Accreditation Committee of OECI. His clinical interest spreads to the CNS, lung, head and neck, GI cancers and lymphomas. Recent years has become a strong advocate of supportive palliative care especially of nutrition therapy in cancer patients. This year he moved to Oslo and currently works at the Oslo University Hospital – Radiumhospital as consultant oncologist and member of the proton therapy team.

Selected recent papers:

 Molnár A, Pálfi E, Belák B, Blasszauer C, Reibl D, Lövey J. Positive correlation between persistence of medical nutrition therapy and overall survival in patients with head and neck cancer. Pathol Oncol Res 2024; 30: 1611664.
 Tóth E, Kürönya Z, Soós E, Pintér T, Butz H, Horváth Z, Csernák E, Grolmusz VK, Székely J, Straussz T, Lövey J, Jánvári L, Báthory-

Fülöp L, Nagy P, Polgár C, Patócs, A. Application of comprehensive molecular genetic profiling in precision cancer medicine, Hungarian experiences. Acta Oncol 2024; 63: 433–440.

 Lövey J, Molnar A and B. Banky. Long-term nutrition in patients candidate to neoadjuvant and adjuvant treatments. Eur J Surg Oncol 2023; 50: 5.
 Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, Harrington K, Chang PM, Lin JC, Razaq MA, Teixeira MM, Lövey J, Chamois J, Rueda A, Hu C, Dunn LA, Dvorkin MV, De Beukelaer S, Pavlov D, Thurm H, Cohen E. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 2021; 22(4): 450–462.

On the occasion of Brno Oncology Days, Dr. Lövey will deliver an invited lectures on the topic "Persistence of nutrition and survival in head and neck cancer patients, based on real-life data".



Prof. Álvaro Pinto, MD, PhD

Medical Oncology Department, University Hospital La Paz, Autonoma University Madrid, Spain CURRENT OPTIONS FOR FIRST-LINE PALLIATIVE SYSTEMIC THERAPY IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA Thursday 24. 10. 2024, 11:15 a.m., R. Werner Hall IMPLEMENTATION OF PRECISION MEDICINE IN UROLOGIC ONCOLOGY Friday 25. 10. 2024, 1:10 p.m., R. Werner Hall

Álvaro Pinto studied the degree in Medicine in Valladolid University (1996– 2002). After that, he specialized in Medical Oncology in the University Hospital La Paz in Madrid, from 2003–2007. Together with that, he obtained his PhD in Medicine in 2009, with a work focused on the role of genomic profiles for predicting risk of relapse and survival in solid tumors.

From 2010, he is the coordinator of the Urologic Oncology Unit in the Medical Oncology Department at the University Hospital La Paz, and also acts as a co-director of the Urologic Oncology Tumor Board of the institution. He leads the clinical research in urologic tumors and is also a translational researcher in the Institute of Research of the institution, IdiPAZ. Álvaro Pinto is a member of the Board of Directors of two cooperative groups in Spain dedicated to urologic oncology. One of them is Grupo Centro, mainly focused on educational activities in the region of Madrid and its surroundings. The other one is GUARD Consortium (GenitoUrinary Alliance for Research and Development), a multidisciplinary group focused in clinical and translational research in urologic neoplasms.

Due to his interest in research, Álvaro Pinto has received several grants, both form sponsors like BMS and Pfizer, and also from national and European research programs (Spanish Ministry of Health, Spanish Ministry of Science, European Proteomics Program EPIC-XS).

Selected recent papers:

 Pinto A, Miranda M, Pertejo A et al. Different outcomes among patients with intermediate risk metastatic renal cell carcinoma treated with first-line tyrosine-kinase inhibitors. Clin Transl Oncol 2024; 26: 532–537.
 Font A, Mellado B, Climent MA et al. Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1). Br J Cancer 2024; 130: 434–441.
 Pinto A, Reig O, Iglesias C et al. Clinical factors associated with long-term benefit in patients with metastatic renal cell carcinoma treated with axitinib: real-world AXILONG study. Clin Genitourin Cancer 2022; 20: 25–34.
 Lee CH, Shah AY, Rasco D et al. Lenvatinib plus pembrolizumab in patients with either treatment-naïve or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol 2021; 22: 946–958.

On the occasion of Brno Oncology Days, Prof. Pinto will deliver an invited lectures on the topic "Current options for first-line palliative systemic therapy in patients with metastatic urothelial carcinoma" and "Implementation of precision medicine in urologic oncology".



Silke Tribius, MD

Asklepios Tumorzentrum Hamburg, Germany STATE OF ART OF CURRENT HEAD AND NECK TREATMENT Friday 25. 10. 2024, 8:55 a.m., R. Werner Hall PRECISION ONCOLOGY IN HEAD AND NECK TUMOURS Friday 25. 10. 2024, 12:25 p.m., R. Werner Hall

After gaining my first research experience at MSKCC in New York City, I started my residency training in Radiation Oncology in 1997 under the tutelage of B. Vikram, MD, at Montefiore Medical Center / Albert Einstein College of Medicine in the Bronx, NY.

In 2001, I moved back to Germany and continued my academic career at the University Medical Center Hamburg-Eppendorf. Head and neck cancer remained my clinical and scientific focus. I did my PhD in 2013 at the University Medical Center Hamburg-Eppendorf with focus on locally advanced head and neck cancer – from precision in technique to precision in therapy. To me, minimizing late radiation induced toxicity is one of the major goals in optimizing multimodal treatment. I am an active member of national and international societies and involved in various research collaborations.

In 2016, I became the Chief of the Department of Radiation Oncology at the Asklepios Hospital St. Georg, one of the major teaching hospitals of the University Medical Center Hamburg-Eppendorf, Germany and part of the Asklepios Tumorzentrum Hamburg (ATZHH).

I am an enthusiastic medical doctor, teacher and researcher. With my international background and deep understanding about the power of collaboration, I joined the EORTC Head and Neck Cancer Group and international collaborative groups early on. A few years ago, I served as the secretary of the group under the presidency of Prof. Vincent Gregoire. It was my goal not only to support Prof. Gregoire but also to give the group a strong profile and keep it in its multidisciplinary spirit together. On that note, as the recently elected new chair of the EORTC HNCG I wish to continue this work together with all members.

Selected recent papers:

 Baliga S, Abou-Foul AK, Parente P, Szturz P, Thariat J, Shreenivas A, Nankivell P, Bertolini F, Biau J, Blakaj D, Brennan S, Brunet A, De Oliveira TB, Burtness B, Maseda AC, Chow VL, Chua ML, de Ridder M, Garikipati S, Hanai N, Ho FCH, Huang SH, Kiyota N, Klinghammer K, Kowalski LP, Kwong DL, McDowell LJ, Merlano MC, Nair S, Economopoulou P, Overgaard J, Psyrri A, Tribius S, Waldron J, Yom SS, Mehanna HEssential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database. Eur J Cancer 2024; 203: 114038.
 Butt Y, Tennstedt P, Busch CJ, Hanken H, Krüll A, Petersen C, Tribius S. Traditional risk factors and nodal yield-still relevant with high-quality risk--adapted adjuvant treatment for locally advanced head and neck cancer? Strahlenther Onkol 2023; 199(3): 284–292.

3. Tribius S, Haladyn S, Hanken H, Busch CJ, Krüll A, Petersen C, Bergelt C. Parotid sparing and quality of life in long-term survivors of locally advanced head and neck cancer after intensity-modulated radiation therapy. Strahlenther Onkol 2021; 197(3): 219–230.

On the occasion of Brno Oncology Days, Dr. Tribius will deliver an invited lectures on the topic "State of art of current head and neck treatment" and "Precision oncology in head and neck tumours".



Prof. Martin J. van den Bent, MD, PhD

Brain Tumor Center at Erasmus MC Cancer Center, Rotterdam, Netherlands

BREAKING NEWS IN LOW GRADE GLIOMAS

Thursday 24. 10. 2024, 3:10 p.m., R. Werner Hall

Prof. dr. Martin J. van den Bent is trained as a neurologist. He joined in 1992 the Neuro-Oncology Unit of Erasmus MC Cancer Center in Rotterdam, the Netherlands. In 2007 he became professor of Neuro-Oncology at Erasmus University. He has been the principle investigator of many international multicenter phase II and III trials on both high and low grade glial tumors that contributed to the standard of care of glioma patients.

From 2003 to 2009 he was the chair of the EORTC Brain Tumor Group, from 2012 to 2018 he served as a board member of the EORTC. Between 2018 and 2020 he was president of the European Association of NeuroOncology. From 2020 to 2022 he served as the chair of the EANO guideline committee, of which committee he is now a regular member.

Prof. van den Bent served on several ASCO committees including the CNS guideline committee. He is one of the coordinating members of the Response Assessment in Neuro-

-Oncology (RANO) group. He authored many manuscripts on neurooncological topics and wrote many chapters in textbooks on neuro-oncology. He is the recipient of several SNO awards for Excellence in Clinical Research and the 2015 European CanCer Organisation Clinical Research Award.

He organized between 2006 and 2015 the biannual EORTC--EANO-ESMO Trends in Central Nervous System Malignancies. In 2023, he was the president of the EANO annual congress, held in Rotterdam, the Netherlands.

Selected recent papers:

1. Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, de Groot J, Koh E, Law I, Le Rhun E et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol 2024; 25(1): e29-e41.

2. Wen PY, van den Bent M, Youssef G, Cloughesy TF, Ellingson BM, Weller M, Galanis E, Barboriak, DP, de Groot J, Gilbert MR et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol 2023; 41(33): 5187–5199.

3. van den Bent MJ, Geurts M, French PJ, Smits M, Capper D, Bromberg JEC, Chang SM. Primary brain tumours in adults. Lancet 2023; 402(10412): 1564–1579.

4. Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F et al.; INDIGO Trial Investigators. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med 2023; 389(7): 589–601.

 Mair MJ, Bartsch R, Le Rhun E, Berghoff AS, Brastianos PK, Cortes J, Gan HK, Lin NU, Lassman AB, Wen PY, Weller M, van den Bent M, Preusser M. Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours. Nat Rev Clin Oncol 2023; 20(6): 372–389.

On the occasion of Brno Oncology Days, Prof. van den Bent will deliver an invited lecture on the topic "Breaking news in low grade gliomas".



Prof. Winette van der Graaf, PhD

President of the European Organisation for Research and Treatment of Cancer SYSTEMIC TREATMENT OF SARCOMAS Friday 25. 10. 2024, 11:05 a.m., R. Werner Hall PRECISION ONCOLOGY IN SARCOMAS

Friday 25. 10. 2024, 12:10 p.m., R. Werner Hall

Professor Winette van der Graaf, with a PhD on multidrug resistance in cancer, is head of the department of Medical Oncology and Group Leader in the Netherlands Cancer Institute Amsterdam and holds her chair in transformative medical oncology at Erasmus Medical Center in Rotterdam, the Netherlands.

From 2015 to 2018 she was Teamleader Clinical and Translational Sarcoma research at The Institute of Cancer Research, London, UK and consultant in the sarcoma unit of The Royal Marsden Hospital in London. She raised and chairs the Dutch AYA 'Young and Cancer' network. She has published over 550 papers.

She was chair of the Soft Tissue and Bone sarcoma Group from 2011 to 2014 and has been on the board of EORTC since 2015. She is president of the EORTC since February 2022. She is also board member of the European Cancer Organisation.

Selected recent papers:

 van der Laan P, van der Graaf, WTA, van den Broek D, van Boven H, Heeres BC, Schrage Y, Haas RL, Steeghs N, van Houdt WJ.
 Interleukin-6 in relation to early recurrence in primary, localized soft tissue sarcoma: An addition for existing risk classification systems? Eur J Surg Oncol 2024; 50(9): 108530.

 Westerdijk K, Krens SD, Steeghs N, van der Graaf WTA, Tjwa ETTL,
 Westdorp H, Desar IME, van Erp NP. Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients. Cancer Chemother Pharmacol 2024; 93(4): 353–364.
 Roets E, Schuster K, Bickley S, Wartenberg M, Gonzato O,
 Fernandez N, Kasper B, Pilgermann K, Wilson R, Steeghs N, van der Graaf
 WTA, van Oortmerssen G, Husson O. Setting the international research agenda for sarcomas with patients and carers: results of phase II of the Sarcoma Patient Advocacy Global Network (SPAGN) priority setting partnership. BMC Cancer 2024; 24(1): 962.

4. van der Laan P, van der Graaf WTA, Reijers SJM, Schrage YM, Hendriks JJH,
Haas RL, van den Broek D, Steeghs N, van Houdt WJ. Elevated preoperative serum interleukin-6 level is predictive for worse postoperative outcome after soft tissue sarcoma surgery. Eur J Surg Oncol 2023; 49(9): 106926.
5. Strauss SJ, Frezza AM, Abecassis N, Bajpai J, Bauer S, Biagini R,
Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K,
Brennan B, Brodowicz T, Buonadonna A, de Álava E, Dei Tos AP, Garcia Del
Muro X, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V,
Ferrari A, Gaspar N, Gasperoni S ... van der Graaf, WTA et al; ESMO Guidelines
Committee, EURACAN, GENTURIS and ERN PaedCan. Bone sarcomas: ESMOEURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis,
treatment and follow-up. Ann Oncol 2021; 32(12): 1520–1536.

On the occasion of Brno Oncology Days, Prof. van der Graaf will deliver an invited lectures on the topic "Systemic treatment of sarcomas" and "Precision oncology in sarcomas".



Prof. Maximilian Schmid, MD, PhD Department of Radiation Oncology, Medical University of Vienna, Austria

RADIOTHERAPY IN SOFT TISSUE SARCOMAS

Friday 25. 10. 2024, 10:40 a.m., R. Werner Hall

Maximilian Schmid is a radiation oncologist at the Department of Radiation Oncology at the Medical University of Vienna.

Since 2022, he has served as the 2nd Deputy Head of the Department of Radiation Oncology at the Medical University of Vienna, where he also leads the brachytherapy division. He is clinically in charge of the treatment of sarcoma and gynecological cancer.

His research interest is focused on IGABT, use of MRI in radiotherapy and treatment of cervical and vaginal cancer. Maximilian Schmid is part of the coordinators of the EMBRACE studies and head of a Christian Doppler Laboratory for image and knowledge driven precision radiation oncology.

He is an active member of key medical societies, including the European Society for Therapeutic Radiology and Oncology (ESTRO) and the Austrian Muskuloskeletal Oncology Society (AMSOS).

Prof. Schmid has received the ÖGRO Prize for Best Publication in both 2012 and 2016 and holds a patent on innovative methods and systems for brachytherapy planning based on imaging data.

Selected recent papers:

1. Peschek LS, Hobusch GM, Funovics PT, Willegger M, Schmid MP, Amann G, Lamm W, Brodowicz T, Ay C, Windhager R, Panotopoulos J. High fibrinogen levels are associated with poor survival in patients with liposarcoma. Sci Rep 2023; 13(1): 8608.

2. Schmid MP, Harrabi S, Herfarth K, Bruland ØS, Welzel T, Haberer T, Ellerbrock M, Debus J, Uhl M, Seidensaal K. Particle Therapy in Adult Patients with Pelvic Ewing Sarcoma-Tumor and Treatment Characteristics and Early Clinical Outcomes. Cancers (Basel). 2022; 14(24): 6045.

3. Seidensaal K, Dostal M, Liermann J, Adeberg S, Weykamp F, Schmid MP, Freudlsperger C, Hoffmann J, Hompland I, Herfarth K, Debus J, Harrabi SB. Inoperable or incompletely resected craniofacial osteosarcoma treated by particle radiotherapy. Front Oncol 2022; 12: 927399.

On the occasion of Brno Oncology Days, Prof. Schmid will deliver an invited lectures on the topic "Radiotherapy in soft tissue sarcomas".

NOTES:	

Diagnostic and treatment centres in MMCI

The MMCI has **22 diagnostic and treatment centres**, which focus on different cancer types, treatment procedures or supportive care services.

Treatment centres deliver comprehensive cancer care based on interdisciplinary teamwork of specialist physicians and other non-medical healthcare professionals.

The concept of treatment centres enables us to provide **high-quality medical services** to MMCI patients and to share our expertise with other healthcare institutions within the region. Furthermore, MMCI provides **access to the most innovative diagnostics** and cancer treatment options **including robotic surgery**, **theranostics, precision oncology and radiotherapy**.



Breast Cancer Centre Centres for Gastrointestinal tumors

- Centre for Oesophageal and Gastric Cancer
- Colon Cancer Centre
- Centre for Liver and Biliary Tract Cancer
- Centre for Pancreatic Cancer
- **Centres for Urologic tumors**
 - Prostate Cancer Centre
 - Kidney and Urinary Tract Cancer Centre
 - Testicular Cancer Centre
- **Centres for Gynecologic tumors**
 - Centre for Ovarian, Tubal and Peritoneal Cancers
 - Centre for Uterine, Cervical and Vulvar Cancers

Centre for Lung and Pleural Cancer Centre for Skin Cancer and Melanoma Centre for Brain and Spinal Cord Tumours Head and Neck Cancer Centre Sarcoma centre Centre for Neuroendocrine Tumours Thyroid Cancer Centre Centre for cancer of unknown primary and other rare malignancies Centre for Precision Oncology Robotic Surgery Centre Centre for Palliative Medicine and Pain Management Centre for cytoreduction and regional chemotherapy

Masaryk Memorial Cancer Institute




Masaryk Memorial Cancer Institute (MMCI) is **the largest cancer centre in the Czech Republic** in terms of the number of primarily treated adult patients with solid tumors and the provision of preventive cancer care. **Almost 5 000 newly diagnosed cancer patients** start treatment in MMCI every year. MMCI currently plays the role of the National cancer centre in the network of Czech Comprehensive Cancer Centres.

MMCI is an internationally recognized Institute, an accredited member of **the Organisation of European Cancer Institutes (OECI)** and **ESMO Designated Centre of Integrated Oncology and Palliative Care**. MMCI is also a member of ERN network for rare adult solid cancers EURACAN and for genetic tumor risk syndromes GENTURIS.

MMCI serves as a national node of the **BBMRI-ERIC** research infrastructure for biobanking and is a partner of Czech Clinical Research Infrastructure Network (CZECRIN).

1,123 employees, of whom 131 hold a scientific degree
220 inpatient beds / 8,432 inpatient cases
44 beds in 2 day care units / 32 078 treatment applications
52 number of outpatient clinics / 578,103 outpatient treatments
5,552 operations, including robotic surgeries
650,923 radiotherapy procedures
192 peer-reviewed publications
127 clinical trials
A+ rating from patients

MMCI is providing health care services, research and education in the areas of prevention, diagnosis and treatment of solid tumors. MMCI is affiliated to Masaryk University, within which it cooperates with two other university hospitals: University Hospital Brno and St. Anne's University Hospital. MMCI operates its own facility for basic and translational research called **RECAMO** (Research Centre for Applied Molecular Oncology) and provides full support for clinical research, including Phase I Clinical Trial Unit, biobanking and precision oncology programme.







ESMO DESIGNATED CENTRES of integrated oncology and palliative care services





